• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Immunization with live attenuated A/H5N1 vaccine protects guinea pigs from reinfection

tetano

Editor, Senior Moderator
Vopr Virusol. 2013 Nov-Dec;58(6):36-9.
[Immunization with live attenuated A/H5N1 vaccine protects guinea pigs from reinfection].
[Article in Russian]
[No authors listed]
Abstract

Cold-adapted influenza virus A/HK/1/68/162/35(H3N2) was developed as unified donor of attenuation and high reproductive capacity forvaccine strains. The reassortant of this donor with surface antigens of highly pathogenic strain Alchicken/Astana/6/05 (H5N1) was tested in guinea pigs as a live or inactivated preparation. Immunization with both formulations induced equal levels of serum virus specific antibodies, while the level of mucosal antibodies was significantly higher in animals immunized with live virus. The challenge with the homologous virus demonstrated complete virus clearance only in this group, thereby indicating a direct correlation of the protection level with the level of mucosal antibodies.

PMID:
24772645
[PubMed - in process]

http://www.ncbi.nlm.nih.gov/pubmed/24772645
 
Back
Top Bottom